John W Rose
Physician in Salt Lake City, UT
License number
Utah 173744-1205
Issued Date
Aug 1, 1985
Expiration Date
Jan 31, 2018
Category
Physician
Type
Physician & Surgeon
Address
Address
Salt Lake City, UT
Professional information
Dr. John W Rose, Salt Lake City UT - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
University Utah Neurology Clinc
729 Arapeen Dr, Salt Lake City 84108
(801) 585-7575 (Phone)
729 Arapeen Dr, Salt Lake City 84108
(801) 585-7575 (Phone)
Certifications:
Neurology, 1981
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Maryland At Baltimore / Professional Schools
Graduated: 1975
University of Maryland At Baltimore / Professional Schools
Graduated: 1975
Sales Manager At Deseret Book Company
Position:
Sales Manager at Deseret Book Company
Location:
Greater Salt Lake City Area
Industry:
Publishing
Work:
Deseret Book Company
since May 2007
-
Sales Manager
Anderson Merchandisers
Dec 1997 - May 2007
-
Regional Sales Manager
Education:
Western Governors University 2012 - 2013
BS, Business Management University of Nevada-Las Vegas 1988 - 1991
BS, Hotel Administration
BS, Business Management University of Nevada-Las Vegas 1988 - 1991
BS, Hotel Administration
Methods For Identification And Prediction Of Multiple Sclerosis Disease And Therapy Response
US Patent:
2010016, Jul 1, 2010
Filed:
Sep 21, 2009
Appl. No.:
12/563995
Inventors:
John W. Rose - Salt Lake City UT, US
Mark F. Leppert - Salt Lake City UT, US
Mark F. Leppert - Salt Lake City UT, US
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT
LINEAGEN, INC. - Salt Lake City UT
LINEAGEN, INC. - Salt Lake City UT
International Classification:
G01N 33/564
US Classification:
436506
Abstract:
Methods and compositions for diagnosing multiple sclerosis (“MS”) in an individual or the predisposition or risk of MS, and for the prediction of the response to treatment of MS in an individual. More particularly, methods and compounds for the use of clinical, neuroradiological, genetic, biological and/or immunological markers as prognostic indicators, diagnostic markers, or predictors of response to MS therapy.